Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Phenotypic and functional features of B cells from two different human subcutaneous adipose depots

Frasca D., Garcia D., Diaz A., Romero M., Thaller S., Blomberg BB.

Prospective Study on Autoimmune Research, published in PLoS One (2023) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
PLoS One (2023)
Reported sample size
—
Source database
Europe PMC
PMID
37104286
PMCID
PMC10138852
DOI
10.1371/journal.pone.0285025
Citations
5

Abstract (original English)

In this study, we have compared frequencies, phenotype, function and metabolic requirements of B cells isolated from the breast and abdominal subcutaneous adipose tissue (AT) of women with obesity who underwent weight reduction surgeries. Results show that B cells from the abdominal AT are more inflammatory than those from the breast, characterized by higher frequencies of inflammatory B cell subsets and higher expression of RNA for inflammatory markers associated with senescence. Secretion of autoimmune antibodies is also higher in the abdominal AT as compared to the breast, and is associated with higher frequencies of autoimmune B cells with the membrane phenotype CD21lowCD95+ B cells expressing the transcription factor T-bet. Moreover, glucose uptake is higher in B cells from the abdominal AT as compared to the breast, thereby suggesting a better capacity to perform glycolysis, needed to support intrinsic B cell inflammation and autoimmune antibody secretion.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueHumansObesityAutoantibodiesPhenotypeFemaleSubcutaneous FatAbdominal FatAdipositySubcutaneous Fat, Abdominal

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research